Oncolytic activity of HF10 in head and neck squamous cell carcinomas

Shinichi Esaki, Fumi Goshima, Haruka Ozaki, Gaku Takano, Yoshimi Hatano, Daisuke Kawakita, Kei Ijichi, Takahiro Watanabe, Yoshitaka Sato, Takayuki Murata, Hiromitsu Iwata, Yuta Shibamoto, Shingo Murakami, Yukihiro Nishiyama, Hiroshi Kimura

Research output: Contribution to journalArticle

Abstract

Recent developments in therapeutic strategies have improved the prognosis of head and neck squamous cell carcinoma (HNSCC). Nevertheless, 5-year survival rate remains only 40%, necessitating new therapeutic agents. Oncolytic virotherapy entails use of replication-competent viruses to selectively kill cancer cells. We aimed to explore the potential of HF10 as an oncolytic virus against human or mouse HNSCC cell lines, and primary-cultured HNSCC cells. HF10 replicated well in all the HNSCC cells, in which it induced cytopathic effects and cell killing. Next, we investigated the oncolytic effects of HF10 in ear tumor models with human or mouse tumor cells. We detected HF10-infected cells within the ear tumors based on their expression of green fluorescent protein. HF10 injection suppressed ear tumor growth and prolonged overall survival. In the syngeneic model, HF10 infection induced tumor necrosis with infiltration of CD8-positive cells. Moreover, the splenocytes of HF10-treated mice released antitumor cytokines, IL-2, IL-12, IFN-alpha, IFN-beta, IFN-gamma, and TNF-alpha, after stimulation with tumor cells in vitro. The HF10-treated mice that survived their original tumor burdens rejected tumor cells upon re-challenge. These results suggested that HF10 killed HNSCC cells and induced antitumoral immunity, thereby establishing it as a promising agent for the treatment of HNSCC patients.

Original languageEnglish
JournalCancer Gene Therapy
DOIs
Publication statusAccepted/In press - 01-01-2019

Fingerprint

Neoplasms
Ear
Oncolytic Virotherapy
Carcinoma, squamous cell of head and neck
Oncolytic Viruses
Interleukin-12
Virus Replication
Green Fluorescent Proteins
Tumor Burden
Interleukin-2
Immunity
Necrosis
Therapeutics
Survival Rate
Tumor Necrosis Factor-alpha
Cytokines
Cell Line
Injections
Survival
Growth

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research

Cite this

Esaki, S., Goshima, F., Ozaki, H., Takano, G., Hatano, Y., Kawakita, D., ... Kimura, H. (Accepted/In press). Oncolytic activity of HF10 in head and neck squamous cell carcinomas. Cancer Gene Therapy. https://doi.org/10.1038/s41417-019-0129-3
Esaki, Shinichi ; Goshima, Fumi ; Ozaki, Haruka ; Takano, Gaku ; Hatano, Yoshimi ; Kawakita, Daisuke ; Ijichi, Kei ; Watanabe, Takahiro ; Sato, Yoshitaka ; Murata, Takayuki ; Iwata, Hiromitsu ; Shibamoto, Yuta ; Murakami, Shingo ; Nishiyama, Yukihiro ; Kimura, Hiroshi. / Oncolytic activity of HF10 in head and neck squamous cell carcinomas. In: Cancer Gene Therapy. 2019.
@article{9e2f4d9b10cc481abda2dcdd0792b0de,
title = "Oncolytic activity of HF10 in head and neck squamous cell carcinomas",
abstract = "Recent developments in therapeutic strategies have improved the prognosis of head and neck squamous cell carcinoma (HNSCC). Nevertheless, 5-year survival rate remains only 40{\%}, necessitating new therapeutic agents. Oncolytic virotherapy entails use of replication-competent viruses to selectively kill cancer cells. We aimed to explore the potential of HF10 as an oncolytic virus against human or mouse HNSCC cell lines, and primary-cultured HNSCC cells. HF10 replicated well in all the HNSCC cells, in which it induced cytopathic effects and cell killing. Next, we investigated the oncolytic effects of HF10 in ear tumor models with human or mouse tumor cells. We detected HF10-infected cells within the ear tumors based on their expression of green fluorescent protein. HF10 injection suppressed ear tumor growth and prolonged overall survival. In the syngeneic model, HF10 infection induced tumor necrosis with infiltration of CD8-positive cells. Moreover, the splenocytes of HF10-treated mice released antitumor cytokines, IL-2, IL-12, IFN-alpha, IFN-beta, IFN-gamma, and TNF-alpha, after stimulation with tumor cells in vitro. The HF10-treated mice that survived their original tumor burdens rejected tumor cells upon re-challenge. These results suggested that HF10 killed HNSCC cells and induced antitumoral immunity, thereby establishing it as a promising agent for the treatment of HNSCC patients.",
author = "Shinichi Esaki and Fumi Goshima and Haruka Ozaki and Gaku Takano and Yoshimi Hatano and Daisuke Kawakita and Kei Ijichi and Takahiro Watanabe and Yoshitaka Sato and Takayuki Murata and Hiromitsu Iwata and Yuta Shibamoto and Shingo Murakami and Yukihiro Nishiyama and Hiroshi Kimura",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41417-019-0129-3",
language = "English",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",

}

Esaki, S, Goshima, F, Ozaki, H, Takano, G, Hatano, Y, Kawakita, D, Ijichi, K, Watanabe, T, Sato, Y, Murata, T, Iwata, H, Shibamoto, Y, Murakami, S, Nishiyama, Y & Kimura, H 2019, 'Oncolytic activity of HF10 in head and neck squamous cell carcinomas', Cancer Gene Therapy. https://doi.org/10.1038/s41417-019-0129-3

Oncolytic activity of HF10 in head and neck squamous cell carcinomas. / Esaki, Shinichi; Goshima, Fumi; Ozaki, Haruka; Takano, Gaku; Hatano, Yoshimi; Kawakita, Daisuke; Ijichi, Kei; Watanabe, Takahiro; Sato, Yoshitaka; Murata, Takayuki; Iwata, Hiromitsu; Shibamoto, Yuta; Murakami, Shingo; Nishiyama, Yukihiro; Kimura, Hiroshi.

In: Cancer Gene Therapy, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Oncolytic activity of HF10 in head and neck squamous cell carcinomas

AU - Esaki, Shinichi

AU - Goshima, Fumi

AU - Ozaki, Haruka

AU - Takano, Gaku

AU - Hatano, Yoshimi

AU - Kawakita, Daisuke

AU - Ijichi, Kei

AU - Watanabe, Takahiro

AU - Sato, Yoshitaka

AU - Murata, Takayuki

AU - Iwata, Hiromitsu

AU - Shibamoto, Yuta

AU - Murakami, Shingo

AU - Nishiyama, Yukihiro

AU - Kimura, Hiroshi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Recent developments in therapeutic strategies have improved the prognosis of head and neck squamous cell carcinoma (HNSCC). Nevertheless, 5-year survival rate remains only 40%, necessitating new therapeutic agents. Oncolytic virotherapy entails use of replication-competent viruses to selectively kill cancer cells. We aimed to explore the potential of HF10 as an oncolytic virus against human or mouse HNSCC cell lines, and primary-cultured HNSCC cells. HF10 replicated well in all the HNSCC cells, in which it induced cytopathic effects and cell killing. Next, we investigated the oncolytic effects of HF10 in ear tumor models with human or mouse tumor cells. We detected HF10-infected cells within the ear tumors based on their expression of green fluorescent protein. HF10 injection suppressed ear tumor growth and prolonged overall survival. In the syngeneic model, HF10 infection induced tumor necrosis with infiltration of CD8-positive cells. Moreover, the splenocytes of HF10-treated mice released antitumor cytokines, IL-2, IL-12, IFN-alpha, IFN-beta, IFN-gamma, and TNF-alpha, after stimulation with tumor cells in vitro. The HF10-treated mice that survived their original tumor burdens rejected tumor cells upon re-challenge. These results suggested that HF10 killed HNSCC cells and induced antitumoral immunity, thereby establishing it as a promising agent for the treatment of HNSCC patients.

AB - Recent developments in therapeutic strategies have improved the prognosis of head and neck squamous cell carcinoma (HNSCC). Nevertheless, 5-year survival rate remains only 40%, necessitating new therapeutic agents. Oncolytic virotherapy entails use of replication-competent viruses to selectively kill cancer cells. We aimed to explore the potential of HF10 as an oncolytic virus against human or mouse HNSCC cell lines, and primary-cultured HNSCC cells. HF10 replicated well in all the HNSCC cells, in which it induced cytopathic effects and cell killing. Next, we investigated the oncolytic effects of HF10 in ear tumor models with human or mouse tumor cells. We detected HF10-infected cells within the ear tumors based on their expression of green fluorescent protein. HF10 injection suppressed ear tumor growth and prolonged overall survival. In the syngeneic model, HF10 infection induced tumor necrosis with infiltration of CD8-positive cells. Moreover, the splenocytes of HF10-treated mice released antitumor cytokines, IL-2, IL-12, IFN-alpha, IFN-beta, IFN-gamma, and TNF-alpha, after stimulation with tumor cells in vitro. The HF10-treated mice that survived their original tumor burdens rejected tumor cells upon re-challenge. These results suggested that HF10 killed HNSCC cells and induced antitumoral immunity, thereby establishing it as a promising agent for the treatment of HNSCC patients.

UR - http://www.scopus.com/inward/record.url?scp=85071693076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071693076&partnerID=8YFLogxK

U2 - 10.1038/s41417-019-0129-3

DO - 10.1038/s41417-019-0129-3

M3 - Article

AN - SCOPUS:85071693076

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

ER -